Metastatic Renal Cell Carcinoma Clinical Trials Pipeline

New York, USA, Oct. 05, 2022 (GLOBE NEWSWIRE) — Metastatic Renal Cell Carcinoma Clinical Trials Pipeline Landscape Analysis of 45+ Companies by DelveInsight

The prevalence of Metastatic Renal Cell Carcinoma has been rising since the past few years, which prompts the growing demand for the treatment options. The market is driven by the increase prevalence of cancer and the rising geriatric population. The Companies developing the potential therapies in the last stage of development include Genentech, Xynomic Pharmaceuticals, Incyte Corporation, and several others.

DelveInsight’s ‘Metastatic Renal Cell Carcinoma Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline metastatic renal cell carcinoma therapies in various stages of clinical development, major pharmaceutical players working to advance the pipeline space and future growth potential of the metastatic renal cell carcinoma pipeline domain.

Key Takeaways from the Metastatic Renal Cell Carcinoma Pipeline Report

• DelveInsight’s metastatic renal cell carcinoma pipeline analysis depicts a robust space with 45+ active players working to develop 50+ pipeline therapies. 
• Some of the key pharmaceutical players working to develop potential metastatic renal cell carcinoma drug candidates to improve the metastatic renal cell carcinoma treatment landscape include AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4 Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd., Betta Pharmaceuticals, Exelixis, Hutchison Medipharma…